It's been a monumental few days for Moderna (NASDAQ:MRNA). Its stock experienced a significant spike on Monday after the pharma giant announced that phase 1 trials for its prospective COVID-19 vaccine, mRNA-1273, showed promising interim results. Shares closed almost 20% higher on Monday compared with last Friday's final price and were up nearly 340% year to date when the closing gong rang. Meanwhile, the Dow Jones Industrial Average (DJINDICES:^DJI) gained over 900 points on Monday, an increase of just under 4%.
privacy policy | terms of use | contact us | advertise | pharma blogs | facebook | twitter
Copyright © 2025,